Key Points Intuitive pre-announced sales results for Q4 today -- and growth is slowing down. Full-year and Q4 earnings results won't come out for another week. 10 stocks we like better than Intuitive Surgical › Intuitive (NASDAQ: ISRG) stock (the robotic surgery company formerly known as "Intuitive Surgical") tumbled 5.8% through 11 a.m. ET Wednesday despite pre-announcing a sales beat ahead of official Q4 earnings. Analysts expect Intuitive to report $2.7 billion in quarterly sales, but Intuitive ...

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company released its preliminary, unaudited results for Q4 2025, with total revenue coming at ~$1.260 billion, reflecting an increase of 13% YoY. Notably, the US revenue is projected to be ~$892 million, demonstrating 11% growth compared to Q4 2024. DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025 DexCom, Inc. (NASDAQ:DXCM) ended 2025 on a healthy note, with revenue surpassin ...

Company Overview - Treace Medical Concepts is focused on the surgical treatment of bunions and related deformities[7] - The company reported preliminary FY 2025 revenue of $212.3 million to $212.7 million, representing approximately 2% year-over-year growth at the midpoint[7] - Approximately 1/3 of US Foot & Ankle Surgeons used Treace bunion systems in 2025[7] Market Opportunity - Approximately 67 million Americans are affected by bunions[9] - Annually, 4.4 million people seek medical treatment for bunions, with 1.1 million being surgical candidates, representing a $5 billion+ US market opportunity[9] - The current US market for bunion surgical procedures is $2.3 billion, with podiatrists performing 75% of the surgeries and orthopedists performing 25%[9, 11] Technology and Clinical Outcomes - In nearly 90% of bunions, the metatarsal bone is rotated in the frontal plane[15] - Failure to correct the frontal plane component can lead to a 10-12x greater risk of recurrence[18] - Lapiplasty patients experienced early weight bearing at 7.7 days (average) in a walking boot[23] - Lapiplasty patients experienced low recurrence rates of 0.8% (HVA >20°) & 8.4% (HVA >15°) at 48 months[23] - Lapiplasty patients experienced 81% pain reduction with 89% improvement in MOxFQ walking/standing scores at 48 months[23] Future Growth and Strategy - 58% of surgeons expect MIS osteotomies to be their fastest-growing bunion procedure in the next year[35] - 56% of bunion patients would "greatly increase interest" in surgery with an MIS option[36]

Core Viewpoint - Beta Bionics, Inc. has faced significant stock decline following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped by approximately $11.85, or 37.04%, closing at $20.14 [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics due to the significant losses suffered by investors [2]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Insights - Intuitive announced preliminary financial results for Q4 and full year 2025, highlighting significant revenue growth driven by increased procedure volume and system placements [1][3][10] Financial Performance - Q4 2025 revenue is expected to be approximately $2.87 billion, a 19% increase from $2.41 billion in Q4 2024 [3] - Full year 2025 revenue is projected at approximately $10.06 billion, reflecting a 21% increase compared to $8.35 billion in 2024 [3] - Instruments and accessories revenue for Q4 2025 increased by 17% to approximately $1.66 billion, up from $1.41 billion in Q4 2024, driven by an 18% growth in worldwide procedure volume [4] - Full year 2025 instruments and accessories revenue rose by 19% to approximately $6.02 billion, compared to $5.08 billion in 2024 [4] Procedure Volume - Q4 2025 da Vinci procedures increased by approximately 17% compared to Q4 2024, with a total of about 3,153,000 procedures performed in 2025, an 18% increase from approximately 2,683,000 in 2024 [5] - Growth in da Vinci procedure volume was largely due to an 18% increase in U.S. general surgery procedures and a 23% increase in procedures performed outside the U.S. [5] - Worldwide da Vinci procedures are expected to grow by approximately 13% to 15% in 2026 [5] System Placements - In Q4 2025, the company placed 532 da Vinci surgical systems, compared to 493 in Q4 2024, including 303 da Vinci 5 systems [6][8] - For the full year 2025, 1,721 da Vinci surgical systems were placed, an increase from 1,526 in 2024, with 870 being da Vinci 5 systems [9] Revenue Breakdown - Q4 2025 systems revenue was approximately $786 million, up from $655 million in Q4 2024, attributed to increased system placements and higher average selling prices [6][7] - Full year 2025 systems revenue reached approximately $2.47 billion, compared to $1.97 billion in 2024 [7] Company Outlook - CEO Dave Rosa expressed satisfaction with the company's performance, noting increased adoption and utilization of surgical platforms and over 3.1 million da Vinci procedures performed in 2025 [10] - The company is scheduled to present detailed financial results at the J.P. Morgan Healthcare Conference on January 14, 2026 [11]

Four weeks of non-invasive DIFS™ neurostimulation delivers meaningful attention gains alongside objective brain imaging changesHOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a new peer-reviewed clinical study in Molecular Psychiatry demonstrating Nexalin’s Deep Intracranial Frequency Stimulation (DIFS™) technology pro ...

GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that it entered into a securities purchase agreement with an institutional investor to issue and sell, in a private placement priced at-the-market under Nasdaq rules, 3,930,818 shares of common stock (or pre-funded warrants in lieu ...

New Product Line Enhances Continuity of Care Across Clinical and Home SettingsTYLER, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a line of over-the-counter ENFit Syringes designed to meet both feeding and medication delivery clinical ...

Core Insights - Intuitive Surgical's da Vinci 5 is in the early stages of international rollout, representing a long-term growth opportunity, but may face near-term hurdles [1][5] - The company is advancing regulatory clearances and early commercial activities outside the U.S., focusing on a country-specific approach for international adoption [2] - Pricing sensitivity and capital budget constraints are significant challenges in international markets, particularly in Europe and Japan [3] Company Strategy - Intuitive Surgical is adopting a portfolio-based approach to address challenges, utilizing leasing structures and alternative configurations to enhance affordability [4] - The company reported solid growth in utilization in several international markets, which is expected to support recurring revenues from instruments and accessories [4] Market Performance - Intuitive Surgical's shares have increased by 9.7% over the past six months, compared to a 12.8% increase for the industry [11] - The company trades at a forward price-to-earnings ratio of 58.13, which is above the industry average but lower than its five-year median of 71.52 [12] Earnings Estimates - The Zacks Consensus Estimate for Intuitive Surgical's 2026 earnings indicates an 11.1% rise from the previous year's level [13] - Current estimates for the upcoming quarters show a year-over-year growth estimate of 1.81% for the current quarter and 16.57% for the next quarter [16]

Company Achievements - Axogen received FDA approval for its unique nerve graft on December 3, 2025, which is a human tissue-based product aimed at repairing damaged peripheral nerves without requiring nerve tissue from patients, granting the company 12 years of market exclusivity [1] - The company is expected to report approximately $225.2 million in annual revenue for FY 2025, marking its highest revenue to date [6] Stock Performance - Axogen's stock (AXGN) experienced a significant increase of 97.60% in 2025, with seven consecutive months of price gains [2] - CEO Michael D. Dale sold 25,000 shares on December 10, 2025, valued at $750,000, which represented 28.24% of his direct holdings prior to the transaction [5] Product and Market Focus - Axogen specializes in surgical solutions for peripheral nerve injuries, developing biologically active nerve grafts, nerve connectors, nerve protectors, nerve caps, and soft tissue membranes for surgical repair and protection of peripheral nerves [3]